Attention-deficit/hyperactivity disorder (ADHD) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: AEBA6AA396AEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Attention-deficit/hyperactivity disorder (ADHD) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Attention-deficit/hyperactivity disorder (ADHD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Attention-deficit/hyperactivity disorder (ADHD) Understanding

The DelveInsight Attention-deficit/hyperactivity disorder (ADHD) epidemiology report gives a thorough understanding of the Attention-deficit/hyperactivity disorder (ADHD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Attention-deficit/hyperactivity disorder (ADHD) in the US, Europe, and Japan. The report covers the detailed information of the Attention-deficit/hyperactivity disorder (ADHD) epidemiology scenario in seven major countries (US, EU5, and Japan).

Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Perspective by DelveInsight

The Attention-deficit/hyperactivity disorder (ADHD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Attention-deficit/hyperactivity disorder (ADHD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Attention-deficit/hyperactivity disorder (ADHD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Attention-deficit/hyperactivity disorder (ADHD) Detailed Epidemiology Segmentation

The Attention-deficit/hyperactivity disorder (ADHD) epidemiology covered in the report provides historical as well as forecasted Attention-deficit/hyperactivity disorder (ADHD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Attention-deficit/hyperactivity disorder (ADHD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Attention-deficit/hyperactivity disorder (ADHD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Report and Model provide an overview of the global trends of Attention-deficit/hyperactivity disorder (ADHD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Attention-deficit/hyperactivity disorder (ADHD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Attention-deficit/hyperactivity disorder (ADHD)
• The report provides the segmentation of the Attention-deficit/hyperactivity disorder (ADHD) epidemiology

Report Highlights

• 11-year Forecast of Attention-deficit/hyperactivity disorder (ADHD) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Attention-deficit/hyperactivity disorder (ADHD)
• Cases of Attention-deficit/hyperactivity disorder (ADHD) by Mutation Types
• Attention-deficit/hyperactivity disorder (ADHD) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Attention-deficit/hyperactivity disorder (ADHD)?
• What are the key findings pertaining to the Attention-deficit/hyperactivity disorder (ADHD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Attention-deficit/hyperactivity disorder (ADHD) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Attention-deficit/hyperactivity disorder (ADHD)?
• What are the currently available treatments of Attention-deficit/hyperactivity disorder (ADHD)?

Reasons to buy

The Attention-deficit/hyperactivity disorder (ADHD) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Attention-deficit/hyperactivity disorder (ADHD) market
• Quantify patient populations in the global Attention-deficit/hyperactivity disorder (ADHD) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Attention-deficit/hyperactivity disorder (ADHD) therapeutics in each of the markets covered
• Understand the magnitude of Attention-deficit/hyperactivity disorder (ADHD) population by its epidemiology
• The Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

3. ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Attention-deficit/hyperactivity disorder (ADHD) Treatment and Management
6.2. Attention-deficit/hyperactivity disorder (ADHD) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in 7MM (2019-2032)
Table 2: Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in the United States (2019-2032)
Table 4: Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in Germany (2019-2032)
Table 6: Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in France (2019-2032)
Table 8: Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in Italy (2019-2032)
Table 10: Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in Spain (2019-2032)
Table 12: Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in the United Kingdom (2019-2032)
Table 14: Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in Japan (2019-2032)
Table 16: Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in 7MM (2019-2032)
Figure 2 Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in the United States (2019-2032)
Figure 4 Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in Germany (2019-2032)
Figure 6 Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in France (2019-2032)
Figure 8 Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in Italy (2019-2032)
Figure 10 Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in Spain (2019-2032)
Figure 12 Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Attention-deficit/hyperactivity disorder (ADHD) Epidemiology in Japan (2019-2032)
Figure 16 Attention-deficit/hyperactivity disorder (ADHD) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report